Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
Blood Cancer Journal|February 12, 2021
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromesKonstantinos Liapis, Vasileios Papadopoulos, George Vrachiolias, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Leukemia|January 16, 2023
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registriesKonstantinos Liapis, Vasileios Papadopoulos, Charalambos Pontikoglou, et al.
Haematologica|October 15, 2020
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspectiveTheo De Witte, Luca Malcovati, Pierre Fenaux, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|August 22, 2018
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromesRaphael Itzykson, Simon Crouch, Erica Travaglino, et al.
Blood Cancer Journal|February 12, 2021
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromesKonstantinos Liapis, Vasileios Papadopoulos, George Vrachiolias, et al.
Blood Advances|August 13, 2021
A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDSHoward S Oster, Simon Crouch, Alexandra Smith, et al.
Haematologica|June 8, 2019
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Simon Crouch, Marlijn Hoeks, et al.
Leukemia Research|February 7, 2018
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDSLouise de Swart, Alex Smith, Detlef Haase, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
Blood|October 26, 2014
Recurrent ETNK1 mutations in atypical chronic myeloid leukemiaCarlo B Gambacorti-Passerini, Carla Donadoni, Andrea Parmiani, et al.
Leukemia|January 16, 2023
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registriesKonstantinos Liapis, Vasileios Papadopoulos, Charalambos Pontikoglou, et al.
Haematologica|October 15, 2020
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspectiveTheo De Witte, Luca Malcovati, Pierre Fenaux, et al.
Pageof 14